MastOR SAS is a medical device company based in Paris, France, founded in 2019. The company focuses on developing a surgical robot designed to assist with laparoscopy, a minimally invasive surgical technique. This innovative platform aims to enhance access to advanced surgical procedures for surgeons and improve resource utilization in operating rooms. By providing tools that facilitate laparoscopy, MastOR seeks to advance surgical practices and patient care.
Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.
Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants, leveraging its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to manipulate gene expression in plants while preserving their DNA. This innovative approach enables the regulation of various growth processes, including germination, flowering, and overall plant growth, as well as effective weed control. By focusing on the use of natural molecules, Micropep aims to provide sustainable solutions for agricultural challenges.
MastOR SAS is a medical device company based in Paris, France, founded in 2019. The company focuses on developing a surgical robot designed to assist with laparoscopy, a minimally invasive surgical technique. This innovative platform aims to enhance access to advanced surgical procedures for surgeons and improve resource utilization in operating rooms. By providing tools that facilitate laparoscopy, MastOR seeks to advance surgical practices and patient care.
LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.
Elicit Plant is an agro-biotech company focused on enhancing the water resistance of crops and developing innovative phytosterol-based solutions. The company aims to facilitate the ecological transition in agriculture by addressing global challenges posed by climate change, particularly its impact on major crops. Elicit Plant utilizes proprietary technology that leverages phytosterols to improve plant stress resistance and activate natural defenses. Extensive field trials conducted across three continents have shown that these biosolutions are a viable option for farmers, offering consistent and significant returns on investment.
SafeHeal is a medtech company focused on developing innovative medical devices specifically for digestive surgery. Established by MD Start, a medtech accelerator that brings physician inventions to market, SafeHeal has received funding from both MD Start and Sofinnova Partners. The company has been recognized for its contributions to the field, receiving accolades such as the Worldwide Innovation Challenge laureate in 2015 and the Charles Foix grant for its innovations aimed at enhancing the quality of life for elderly individuals. SafeHeal was also acknowledged as the most promising MedTech start-up at the Biovision 2016 investor conference and was a finalist in the global Medtech Innovator competition in 2016.
Meiogenix SAS is a biotechnology company based in Paris, France, that specializes in developing breeding and genomic technologies aimed at unlocking the unexplored genetic diversity of organisms. Established in 2010, Meiogenix offers innovative solutions such as SpiX technology, which enhances homologous recombination in specific regions of the genome, and PhoeniX, a non-genetically modified method that facilitates meiotic recombination in hybrid diploid or polyploid yeast cells. These advancements enable the company to support the development of new products that address pressing global food and industrial challenges, expanding natural biodiversity through natural breeding techniques.
Home Biosciences is a European venture builder focused on the biotechnology sector. The company aims to facilitate scientific breakthroughs by employing an asset-centric operating model. It provides essential funding and operational support, allowing project teams to concentrate on their core objectives. By assembling the appropriate expertise and structure, Home Biosciences helps to foster the growth of sustainable biotech ventures.
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.
Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants, leveraging its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to manipulate gene expression in plants while preserving their DNA. This innovative approach enables the regulation of various growth processes, including germination, flowering, and overall plant growth, as well as effective weed control. By focusing on the use of natural molecules, Micropep aims to provide sustainable solutions for agricultural challenges.
Operator of a drug discovery platform designed to develop immune based therapies, including powerful cell therapies, that create accessible cures for solid tumors and blood cancers. The company's platform offers leveraging epigenetic variation and CAR-T precision genetic engineering technology to target tumorous epitopes that are broadly represented across various cancers, enabling patients to get allogeneic treatments to overcome disease.
CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
Pixium Vision SA is a Paris-based company focused on developing implantable medical devices to address blindness caused by the degeneration of retinal photoreceptor cells. The company is known for its bionic vision system, the PRIMA System, which aims to restore vision and enhance the quality of life for individuals suffering from vision loss. Additionally, Pixium Vision is advancing its retinal implant technologies through devices such as the IRIS1, currently in clinical trials, and the upcoming IRIS2, which promises improved visual acuity. The company is also working on the IRIS3 sub-retinal implant, leveraging cutting-edge advancements in neural processing and micro-electronics. Founded in 2011 as a spin-out from the Vision Institute and Université Pierre et Marie Curie, Pixium collaborates with leading institutions, including Stanford University and Moorfields Eye Hospital, to further its research and development efforts. The company is supported by prominent European venture capital firms.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
Abivax is a clinical-stage biotechnology company based in Paris, France, dedicated to discovering and optimizing treatments for inflammatory diseases, viral infections, and cancer. The company is primarily focused on its lead product, ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis and Crohn’s Disease, as well as for COVID-19. Additionally, ABX464 is being evaluated in Phase IIa trials for rheumatoid arthritis and has completed Phase IIa trials aimed at achieving viral remission in HIV patients. Abivax is also developing ABX 196, an immune enhancer in Phase 1/2 trials for hepatocellular cancer, and ABX 544, a candidate for Ebola treatment based on polyclonal antibodies. Furthermore, the company is conducting research into treatments for Dengue fever, influenza, and respiratory syncytial virus. Abivax collaborates with institutions such as the French National Centre for Scientific Research and the University of Montpellier. Founded in 2013, the company aims to harness the body’s immune response to manage chronic inflammatory conditions effectively.
AblaCare is a Paris-based company founded in 2017 that focuses on addressing infertility related to Polycystic Ovary Syndrome (PCOS). The company has developed a minimally invasive procedure designed to restore ovulation in patients with PCOS, offering a more natural and less medicalized approach to pregnancy. This innovative treatment is performed transvaginally under ultrasound guidance, eliminating the need for general anesthesia. The procedure can be conducted in a clinic setting, utilizing techniques similar to those used by fertility specialists in in vitro fertilization (IVF). Through its solution, AblaCare aims to enhance the reproductive health and pregnancy experiences of women affected by PCOS.
Microphyt, founded in 2007 and headquartered in Baillargues, France, specializes in the research, development, production, and marketing of natural algae-based products. The company focuses on microalgae and other photosynthetic microorganisms, targeting sectors such as beauty care, food, health, and energy. Its offerings include dietary supplements and products aimed at promoting weight loss and enhancing brain health. Utilizing industrial-scale cultivation techniques, Microphyt preserves the integrity of microalgae cells to produce biomass and extracts in commercial quantities. This approach enables the healthcare industry to meet the growing demand for innovative personal care and food products.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
Afyren is a sustainable chemistry company based in Saint-Beauzire, France, focused on the valorization of non-food biomass to develop environmentally friendly alternatives to petroleum-based products. Founded in 2012, the company employs innovative biotechnological processes using natural microorganisms to produce a range of bio-sourced organic acids and a high-value fertilizer. Its services extend to microbiology and bioprocess engineering, supporting various sectors including pharmaceuticals, cosmetics, green chemistry, and biopolymers. Afyren's approach aligns with the principles of a circular, low-carbon economy, emphasizing the importance of waste reduction and sustainable resource utilization.
HighLife SAS is a medtech company that specializes in developing a novel transcatheter mitral valve replacement system aimed at treating patients with mitral regurgitation. Founded in 2010 and headquartered in Paris, France, with an additional office in Irvine, California, the company focuses on providing a minimally invasive prosthetic mitral valve that can be implanted on a beating heart. This approach preserves the native valve structure and respects the surrounding anatomy, ensuring reduced trauma during surgical procedures. HighLife's technology is designed for ease and safety of use, as well as optimal treatment outcomes, allowing for delivery through a transseptal passage via the femoral vein. The system is currently undergoing clinical evaluation to assess its effectiveness in addressing severe heart conditions.
LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics.
SafeHeal is a medtech company focused on developing innovative medical devices specifically for digestive surgery. Established by MD Start, a medtech accelerator that brings physician inventions to market, SafeHeal has received funding from both MD Start and Sofinnova Partners. The company has been recognized for its contributions to the field, receiving accolades such as the Worldwide Innovation Challenge laureate in 2015 and the Charles Foix grant for its innovations aimed at enhancing the quality of life for elderly individuals. SafeHeal was also acknowledged as the most promising MedTech start-up at the Biovision 2016 investor conference and was a finalist in the global Medtech Innovator competition in 2016.
Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants, leveraging its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to manipulate gene expression in plants while preserving their DNA. This innovative approach enables the regulation of various growth processes, including germination, flowering, and overall plant growth, as well as effective weed control. By focusing on the use of natural molecules, Micropep aims to provide sustainable solutions for agricultural challenges.
Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.
HighLife SAS is a medtech company that specializes in developing a novel transcatheter mitral valve replacement system aimed at treating patients with mitral regurgitation. Founded in 2010 and headquartered in Paris, France, with an additional office in Irvine, California, the company focuses on providing a minimally invasive prosthetic mitral valve that can be implanted on a beating heart. This approach preserves the native valve structure and respects the surrounding anatomy, ensuring reduced trauma during surgical procedures. HighLife's technology is designed for ease and safety of use, as well as optimal treatment outcomes, allowing for delivery through a transseptal passage via the femoral vein. The system is currently undergoing clinical evaluation to assess its effectiveness in addressing severe heart conditions.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Zyl is a mobile application designed to help users gather and share memories with friends and family. Launched in 2015 and based in Saint-Maur-des-Fossés, France, Zyl enables users to discover meaningful moments from their photo libraries and share these memories through events created within the app. Users can invite friends to participate in these events, view a shared timeline, and synchronize photos related to those moments. The app addresses the common dilemma of photo sharing, where only a small fraction of memories are shared due to concerns about privacy and social validation. By focusing on fostering genuine connections, Zyl provides a platform for users to relive and share their experiences, promoting interaction and engagement with loved ones. The company, formerly known as Comet, rebranded to Zyl in November 2017.
CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.
MD Start SA is a Swiss-based incubator and fund focused on the medical technology sector, established in 2009. The company specializes in transforming innovative medical ideas into viable business ventures, providing comprehensive support from project creation to operational development. It partners with prominent organizations in the industry, including Medtronic and Sofinnova Partners, to facilitate the growth of medical device start-ups. By employing both strategic and hands-on approaches, MD Start aims to guide these projects through the investment stage and into commercial development, helping to bring new medical technologies to market.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
MedDay is an international biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company is focused on creating disease-modifying therapies that aim to repair and protect the nervous system. By investigating brain metabolism, MedDay seeks to address significant unmet medical needs and improve patient care for those affected by these disorders. The promising outcomes from their clinical trials motivate the company to continue exploring innovative treatment options, ultimately striving to enhance the quality of life for patients and their caregivers in the healthcare community.
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.
CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in manufacturing biobased materials derived from waste streams of the food processing industry. The company has developed Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. Curran is available in paste, slurry, and powder forms, and is used in various applications, including paints and coatings, paper, food, personal care, home care, cosmetics, concrete, and composites. CelluComp distributes its products across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp focuses on sustainable resources, aiming to provide innovative solutions that reduce reliance on hydrocarbon feedstocks while offering cost-effective products for its clients.
ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, focused on drug discovery and development for acute and chronic viral infections. Founded in 2014 by a group of scientists from the Infectiology Research Center, the company has established a unique platform to identify intracellular therapeutic targets and molecules, particularly for human pathogens. ENYO Pharma is developing treatments for significant viral infections, with ongoing programs targeting chronic hepatitis B and severe influenza. Its lead compound, EYP001, is designed to modulate FXR and reduce viral replication, while EYP002 is currently undergoing preclinical studies. The company aims to advance its pipeline into Phase II clinical trials and collaborates closely with research institutions to leverage innovative therapeutic strategies. ENYO Pharma is committed to addressing unmet medical needs in infectious and metabolic diseases, positioning itself as a leader in antiviral therapies.
Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.
Twenga is an online shopping search platform that facilitates product discovery and price comparison across various categories, including fashion, homeware, games, sports, and gardening. Founded in September 2006 by Bastien Duclaux and Cedric Anes, the company is headquartered in London and operates in multiple countries, employing over 120 people. Twenga serves more than 4,000 clients worldwide, providing advanced traffic acquisition solutions for online advertising. The platform enhances advertisers' performance by automating their advertising investments and offering tools for effective retargeting and search engine marketing. By centralizing access to both international and local products, Twenga enables consumers to find a diverse range of items at competitive prices, streamlining the online shopping experience.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in manufacturing biobased materials derived from waste streams of the food processing industry. The company has developed Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. Curran is available in paste, slurry, and powder forms, and is used in various applications, including paints and coatings, paper, food, personal care, home care, cosmetics, concrete, and composites. CelluComp distributes its products across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp focuses on sustainable resources, aiming to provide innovative solutions that reduce reliance on hydrocarbon feedstocks while offering cost-effective products for its clients.
Pixium Vision SA is a Paris-based company focused on developing implantable medical devices to address blindness caused by the degeneration of retinal photoreceptor cells. The company is known for its bionic vision system, the PRIMA System, which aims to restore vision and enhance the quality of life for individuals suffering from vision loss. Additionally, Pixium Vision is advancing its retinal implant technologies through devices such as the IRIS1, currently in clinical trials, and the upcoming IRIS2, which promises improved visual acuity. The company is also working on the IRIS3 sub-retinal implant, leveraging cutting-edge advancements in neural processing and micro-electronics. Founded in 2011 as a spin-out from the Vision Institute and Université Pierre et Marie Curie, Pixium collaborates with leading institutions, including Stanford University and Moorfields Eye Hospital, to further its research and development efforts. The company is supported by prominent European venture capital firms.
MedDay is an international biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company is focused on creating disease-modifying therapies that aim to repair and protect the nervous system. By investigating brain metabolism, MedDay seeks to address significant unmet medical needs and improve patient care for those affected by these disorders. The promising outcomes from their clinical trials motivate the company to continue exploring innovative treatment options, ultimately striving to enhance the quality of life for patients and their caregivers in the healthcare community.
Aledia SA develops and manufactures light-emitting diodes (LEDs). The company offers microwire LED chips based on a 3D architecture using gallium-nitride-on-silicon microwires. It provides its products for general lighting, automotive, and display applications. The company was founded in 2011 and is based in Grenoble, France with subsidiaries in Malacca, Malaysia; and Palo Alto, California.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.
Bee Ware is a developer of web security software applications that focus on securing web applications for both large companies and small to medium enterprises. The company offers solutions that include vulnerability detection, protection of application servers, and management of authentication and authorization. Additionally, Bee Ware ensures the availability and continuity of services, allowing organizations to meet evolving market demands and regulatory obligations while maintaining operational flexibility. By providing these essential services, Bee Ware aids businesses in safeguarding their digital assets and enhancing their overall cybersecurity posture.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
QuesCom S.A., founded in 1999 and headquartered in Sophia Antipolis, France, specializes in designing and manufacturing Internet telecommunication systems. The company offers a range of products including business communication management portals, GSM gateways, SIM servers, and mobile call servers. Its technology encompasses VoIP solutions and network management software, catering to both enterprises and service providers. QuesCom collaborates with established industry partners such as Aastra, Alcatel, Avaya, and Cisco to enhance its offerings and maintain a competitive edge in the telecommunications market.
Crocus Technology International Corp. specializes in developing and supplying magnetic sensors and embedded memory solutions based on its patented magnetic logic unit technology. The company provides a range of magnetic sensor products, which include various architectures suitable for challenging environments, such as oil drilling, fluid level measurements, and solar energy applications. Its offerings cater to diverse sectors, including industrial, automotive, consumer electronics, and the Internet of Things. Additionally, Crocus Technology delivers magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries, addressing needs in telecommunications, networking, storage, computing, and handheld devices. Established in 2014, the company is headquartered in Santa Clara, California, with an additional office in Grenoble, France, and distributes its products through a network of sales distributors both domestically and internationally.
Sensitive Object SA develops electronic products for the touch screen, consumer electronics and computing, outdoor interactive, white good, access control, home automation, health care, industrial control, and interactive digital advertising applications. Its products include touch screens, peripherals, and control panels. Sensitive Object SA was founded in 2003 and is based in Boulogne Billancourt, France. It has operations in Paris, France and Singapore, Singapore.
blueKiwi Software SA specializes in providing enterprise social software tailored for financial firms, high-tech organizations, and professional services agencies. The company's flagship products include blueKiwi 2009, designed for people-centric organizations to foster social networks and collaborative environments among partners, customers, and colleagues, and blueKiwi Pro, which caters specifically to small and medium businesses. In addition to its software solutions, blueKiwi offers strategic consulting and technical services to enhance client operations. The company operates primarily in France and the United Kingdom.
MXP4 develops interactive music solutions that create revenue opportunities for the music, media and marketing industries. Creating a video game-like environment where consumers can play with the music, MXP4-powered applications are proven to drive engagement, viral distribution and music purchases. The MXP4 Everywhere roadmap ensures the interactive music technology is readily available in third party services, apps and music formats for implementation by brands, advertisers, media portals, mobile applications, music distribution platforms and third-party music formats. When a fan sees the MXP4 logo on a music app, it means they can play with the music. MXP4 is led by a team of music industry and digital media experts, including former senior executives of Musiwave, Vivendi Mobile Entertainment, EMI Music and DivX. The company is backed by Orkos Capital, Sofinnova Partners and Ventech.
Streamezzo S.A. is a company based in Paris, France, specializing in the development of mobile media products and solutions. Founded in 2004, it provides a range of tools that enable telecom operators, broadcasters, media companies, and content providers to create, deploy, and manage services on cellular networks. Its key offerings include the Rich Media Software Suite, which features a Rich Media Client for accessing interactive mobile services, a Rich Media Server for service deployment, and a Workbench for multimedia authoring. Additionally, Streamezzo's solutions encompass Interactive Mobile TV, Music Jukebox for music downloads, and dynamic user interfaces that enhance user engagement. The company also offers professional services to support its clients in effectively utilizing these technologies.
Neosens SA specializes in the design and development of sensor technologies aimed at monitoring and controlling water and industrial liquids. Founded in 2001 and headquartered in Labege, France, the company offers solutions that detect dissolved oxygen levels and monitor fouling in various liquid environments. Its sensor systems find applications in a range of industries, including cooling systems, heat exchangers, potable water treatment, ultra-pure water production, and industrial boilers. Additionally, Neosens' technology is utilized in sectors such as food and beverage, pharmaceuticals, pulp and paper, oil, gas, and petrochemicals. The company's innovative approach leverages microelectronic sensors to ensure the quality and integrity of liquid processes in diverse environments.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.
Qosmos SA, founded in 2000 and headquartered in Paris, France, specializes in network intelligence technology, particularly through embedded deep packet inspection (DPI) solutions. The company offers a range of products designed to classify and analyze IP traffic, including ixEngine, a comprehensive software development kit that features a decoding engine, protocol libraries, and real-time traffic classification tools. Their solutions support various applications such as network security, lawful interception, and regulatory compliance. Qosmos also provides professional services, including design and deployment support, as well as probe development services for telecom and enterprise developers. With additional offices in London, Silicon Valley, Tokyo, and Singapore, Qosmos operates as a subsidiary of Enea AB, focusing on transforming networks into information sources that enhance application and service awareness.
Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.
Stentys S.A. is a medical technology company based in Paris, France, specializing in the development and commercialization of innovative solutions for the treatment of acute myocardial infarction and other coronary diseases. Founded in 2006, the company offers a range of products designed for interventional cardiologists, including the Xposition S, a sirolimus-eluting self-apposing coronary stent system, and Serpentis, a sirolimus-eluting stent featuring a bioabsorbable polymer. Other offerings include the MiStent SES, which incorporates an absorbable polymer, and the STENTYS AC aspiration catheter. Stentys operates in various regions, including Europe, the Middle East, Latin America, and Southeast Asia.
Neosens SA specializes in the design and development of sensor technologies aimed at monitoring and controlling water and industrial liquids. Founded in 2001 and headquartered in Labege, France, the company offers solutions that detect dissolved oxygen levels and monitor fouling in various liquid environments. Its sensor systems find applications in a range of industries, including cooling systems, heat exchangers, potable water treatment, ultra-pure water production, and industrial boilers. Additionally, Neosens' technology is utilized in sectors such as food and beverage, pharmaceuticals, pulp and paper, oil, gas, and petrochemicals. The company's innovative approach leverages microelectronic sensors to ensure the quality and integrity of liquid processes in diverse environments.
Inside Secure, founded in 1995 and based in Aix en Provence, France, specializes in open-standard contactless payment and near field communication (NFC) semiconductors and software. The company develops a range of products including contactless reader interface chips, NFC interface circuits, contactless payment platforms, memory chips, and desktop readers. These products are utilized in various applications such as payment, transit, identity verification, and access control across smart cards, key fobs, mobile devices, and POS systems. Inside Secure also provides professional services for integration and adoption, encompassing application development and system integration. The company's clientele includes payment card and mobile phone manufacturers, systems integrators, and financial institutions, with additional offices in Shanghai, Singapore, Warsaw, Seoul, San Francisco, and Boston.
Fovea Pharmaceuticals is a French biopharmaceutical company based in Paris, specializing in the discovery and development of drugs for ocular diseases. Founded in 2005, the company focuses on addressing various eye conditions, including allergic conjunctivitis, diabetic macular edema, and retinitis pigmentosa. Its product portfolio includes FOV1101 Prednisporin for allergic conjunctivitis, a proprietary plasma kallikrein-kinin inhibitor known as FOV2302 for hereditary angioedema, FOV2304 for diabetic macular edema, and FOV2501, an intravitreal formulation targeting retinitis pigmentosa and potentially dry age-related macular degeneration. As of October 30, 2009, Fovea operates as a subsidiary of Sanofi.
Streamezzo S.A. is a company based in Paris, France, specializing in the development of mobile media products and solutions. Founded in 2004, it provides a range of tools that enable telecom operators, broadcasters, media companies, and content providers to create, deploy, and manage services on cellular networks. Its key offerings include the Rich Media Software Suite, which features a Rich Media Client for accessing interactive mobile services, a Rich Media Server for service deployment, and a Workbench for multimedia authoring. Additionally, Streamezzo's solutions encompass Interactive Mobile TV, Music Jukebox for music downloads, and dynamic user interfaces that enhance user engagement. The company also offers professional services to support its clients in effectively utilizing these technologies.
VoluBill S.A. provides real-time monitoring, control, and charging software to communication providers. It provides CHARGE-IT that enables real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a network charging, control, and policy enforcement platform; and CHARGE-IT Dynamic Charging Platform, which enables real-time, pre-pay, post-pay, and now-pay charging and control of data services. The company offers solutions to fixed, mobile, and fixed mobile convergent operators. VoluBill S.A. was founded in 2001 and is based in Montbonnot Saint Martin, France with additional offices in Europe and Asia.
Purple Labs SA specializes in developing mobile Linux software solutions tailored for real-time operating systems (RTOS) and Linux-based mobile devices. The company offers a comprehensive software suite known as The Mobile Linux Platform, which assists in the creation of mobile feature phones. Additionally, it provides an Application suite designed for 3G feature phones, including various browser and messaging applications for both manufacturers and end-users. Purple Labs also produces the Purple Magic, a 3G Linux feature phone that supports video telephony, music playback, high-speed internet browsing, and video streaming. Beyond its software offerings, the company delivers services such as application integration, customization of Linux support packages, hardware design assistance, and product industrialization. Founded in 2001 and headquartered in Le Bourget du Lac, France, Purple Labs maintains offices in multiple countries, including the United States and China. As of 2009, Purple Labs operates as a subsidiary of Myriad Group AG.
Inside Secure, founded in 1995 and based in Aix en Provence, France, specializes in open-standard contactless payment and near field communication (NFC) semiconductors and software. The company develops a range of products including contactless reader interface chips, NFC interface circuits, contactless payment platforms, memory chips, and desktop readers. These products are utilized in various applications such as payment, transit, identity verification, and access control across smart cards, key fobs, mobile devices, and POS systems. Inside Secure also provides professional services for integration and adoption, encompassing application development and system integration. The company's clientele includes payment card and mobile phone manufacturers, systems integrators, and financial institutions, with additional offices in Shanghai, Singapore, Warsaw, Seoul, San Francisco, and Boston.
Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).
MXP4 develops interactive music solutions that create revenue opportunities for the music, media and marketing industries. Creating a video game-like environment where consumers can play with the music, MXP4-powered applications are proven to drive engagement, viral distribution and music purchases. The MXP4 Everywhere roadmap ensures the interactive music technology is readily available in third party services, apps and music formats for implementation by brands, advertisers, media portals, mobile applications, music distribution platforms and third-party music formats. When a fan sees the MXP4 logo on a music app, it means they can play with the music. MXP4 is led by a team of music industry and digital media experts, including former senior executives of Musiwave, Vivendi Mobile Entertainment, EMI Music and DivX. The company is backed by Orkos Capital, Sofinnova Partners and Ventech.
Stentys S.A. is a medical technology company based in Paris, France, specializing in the development and commercialization of innovative solutions for the treatment of acute myocardial infarction and other coronary diseases. Founded in 2006, the company offers a range of products designed for interventional cardiologists, including the Xposition S, a sirolimus-eluting self-apposing coronary stent system, and Serpentis, a sirolimus-eluting stent featuring a bioabsorbable polymer. Other offerings include the MiStent SES, which incorporates an absorbable polymer, and the STENTYS AC aspiration catheter. Stentys operates in various regions, including Europe, the Middle East, Latin America, and Southeast Asia.
blueKiwi Software SA specializes in providing enterprise social software tailored for financial firms, high-tech organizations, and professional services agencies. The company's flagship products include blueKiwi 2009, designed for people-centric organizations to foster social networks and collaborative environments among partners, customers, and colleagues, and blueKiwi Pro, which caters specifically to small and medium businesses. In addition to its software solutions, blueKiwi offers strategic consulting and technical services to enhance client operations. The company operates primarily in France and the United Kingdom.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.
Oxxius SA specializes in the development, design, manufacturing, and sale of diode-pumped solid-state lasers and laser diode modules. Founded in 2002 and headquartered in Lannion, France, the company produces a range of lasers including UV, visible, and infrared options, as well as ultra-stable and single longitudinal mode laser modules. These products serve various applications such as fluorescence analysis in flow cytometry and microscopy, interferometry in laser Doppler velocimetry and holography, and Raman spectroscopy. Oxxius's innovative laser technology offers significant advancements in compactness, reliability, and cost-efficiency, catering to both research and industrial markets. The company distributes its products through a network of partners across multiple countries, ensuring wide accessibility for its offerings in bio-photonics, metrology, and spectroscopy.
Qosmos SA, founded in 2000 and headquartered in Paris, France, specializes in network intelligence technology, particularly through embedded deep packet inspection (DPI) solutions. The company offers a range of products designed to classify and analyze IP traffic, including ixEngine, a comprehensive software development kit that features a decoding engine, protocol libraries, and real-time traffic classification tools. Their solutions support various applications such as network security, lawful interception, and regulatory compliance. Qosmos also provides professional services, including design and deployment support, as well as probe development services for telecom and enterprise developers. With additional offices in London, Silicon Valley, Tokyo, and Singapore, Qosmos operates as a subsidiary of Enea AB, focusing on transforming networks into information sources that enhance application and service awareness.
Varioptic SA provides adjustable lens solutions. Its products include variable focus liquid lenses, liquid lens for focus and astigmatism control, auto focus lens modules, microscope auto focus modules, liquid lens driver ICs, and liquid lens development kits. The company’s products are used in industrial, biometrics, medical, and consumer applications. It sells its products through distributors. The company was founded in 2002 and is based in Lyon, France. As of December 29, 2016, Varioptic SA operates as a subsidiary of Invenios France SAS.
Streamezzo S.A. is a company based in Paris, France, specializing in the development of mobile media products and solutions. Founded in 2004, it provides a range of tools that enable telecom operators, broadcasters, media companies, and content providers to create, deploy, and manage services on cellular networks. Its key offerings include the Rich Media Software Suite, which features a Rich Media Client for accessing interactive mobile services, a Rich Media Server for service deployment, and a Workbench for multimedia authoring. Additionally, Streamezzo's solutions encompass Interactive Mobile TV, Music Jukebox for music downloads, and dynamic user interfaces that enhance user engagement. The company also offers professional services to support its clients in effectively utilizing these technologies.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.
Fovea Pharmaceuticals is a French biopharmaceutical company based in Paris, specializing in the discovery and development of drugs for ocular diseases. Founded in 2005, the company focuses on addressing various eye conditions, including allergic conjunctivitis, diabetic macular edema, and retinitis pigmentosa. Its product portfolio includes FOV1101 Prednisporin for allergic conjunctivitis, a proprietary plasma kallikrein-kinin inhibitor known as FOV2302 for hereditary angioedema, FOV2304 for diabetic macular edema, and FOV2501, an intravitreal formulation targeting retinitis pigmentosa and potentially dry age-related macular degeneration. As of October 30, 2009, Fovea operates as a subsidiary of Sanofi.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.
Endotis discovers, develops, and manufactures cardiovascular therapeutics. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology areas. Its portfolio of products includes EP217609, a neutralizable anti-coagulant for managing extracorporeal blood circulation during open-heart surgery; FondaParinux, an injectable drug for the prevention and treatment of venous thromboembolism; and an oral anti-coagulant for stroke prevention in atrial fibrillation. Endotis was founded in 2003 and is based in Romainville, France.
Sefas Innovation, founded in 1991 and headquartered in Paris, France, specializes in collaborative document composition and production software. With offices in the UK and the US, the company employs over 80 staff and has been serving Fortune 500 clients for more than 15 years. Its flagship product, the Open Print software suite, is designed for sectors such as financial services, banking, insurance, utilities, telecommunications, and the public sector. Open Print enables the design, composition, and production of complex, data-driven B2C documents, allowing organizations to integrate multiple data sources for personalized communications. The software is increasingly utilized to revamp mission-critical documents to align with the latest marketing initiatives, thereby enhancing revenue opportunities. Notable clients in the UK include Nationwide, HBOS, and British Telecom, all of whom have utilized Open Print since the early 2000s.
Bee Ware is a developer of web security software applications that focus on securing web applications for both large companies and small to medium enterprises. The company offers solutions that include vulnerability detection, protection of application servers, and management of authentication and authorization. Additionally, Bee Ware ensures the availability and continuity of services, allowing organizations to meet evolving market demands and regulatory obligations while maintaining operational flexibility. By providing these essential services, Bee Ware aids businesses in safeguarding their digital assets and enhancing their overall cybersecurity posture.
Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.
VoluBill S.A. provides real-time monitoring, control, and charging software to communication providers. It provides CHARGE-IT that enables real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a network charging, control, and policy enforcement platform; and CHARGE-IT Dynamic Charging Platform, which enables real-time, pre-pay, post-pay, and now-pay charging and control of data services. The company offers solutions to fixed, mobile, and fixed mobile convergent operators. VoluBill S.A. was founded in 2001 and is based in Montbonnot Saint Martin, France with additional offices in Europe and Asia.
Sensitive Object SA develops electronic products for the touch screen, consumer electronics and computing, outdoor interactive, white good, access control, home automation, health care, industrial control, and interactive digital advertising applications. Its products include touch screens, peripherals, and control panels. Sensitive Object SA was founded in 2003 and is based in Boulogne Billancourt, France. It has operations in Paris, France and Singapore, Singapore.
Oxxius SA specializes in the development, design, manufacturing, and sale of diode-pumped solid-state lasers and laser diode modules. Founded in 2002 and headquartered in Lannion, France, the company produces a range of lasers including UV, visible, and infrared options, as well as ultra-stable and single longitudinal mode laser modules. These products serve various applications such as fluorescence analysis in flow cytometry and microscopy, interferometry in laser Doppler velocimetry and holography, and Raman spectroscopy. Oxxius's innovative laser technology offers significant advancements in compactness, reliability, and cost-efficiency, catering to both research and industrial markets. The company distributes its products through a network of partners across multiple countries, ensuring wide accessibility for its offerings in bio-photonics, metrology, and spectroscopy.
Innate Pharma S.A. is a clinical-stage biotechnology company based in Marseille, France, focused on developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in immunotherapies that leverage the innate immune system, particularly through its proprietary ANKET platform, which facilitates the creation of novel monoclonal antibodies. Innate Pharma's product pipeline includes several candidates in various stages of clinical development, such as Monalizumab, an immune checkpoint inhibitor for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody for cutaneous T-cell lymphoma. Other notable candidates include Avdoralimab, a therapeutic antibody targeting C5a receptors, and IPH5201, which aims to block the CD39 immunosuppressive pathway. Additionally, the company has formed strategic collaborations and licensing agreements with major pharmaceutical firms, enhancing its research capabilities and market reach. Founded in 1999, Innate Pharma continues to advance its innovative approaches to cancer treatment.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.
Varioptic SA provides adjustable lens solutions. Its products include variable focus liquid lenses, liquid lens for focus and astigmatism control, auto focus lens modules, microscope auto focus modules, liquid lens driver ICs, and liquid lens development kits. The company’s products are used in industrial, biometrics, medical, and consumer applications. It sells its products through distributors. The company was founded in 2002 and is based in Lyon, France. As of December 29, 2016, Varioptic SA operates as a subsidiary of Invenios France SAS.
InfraWorlds is an innovative French startup specializing in embedded Java technologies and solutions for wireless phones. Its technological competencies, coupled with unrivalled graphic creativity, have earned the company a solid reputation among the main players in this booming sector. Built around a team of dedicated professionals, which is soon to be expanded, InfraWorlds is today consolidating its lead in the fast-growing global wireless entertainment market.
Varioptic SA provides adjustable lens solutions. Its products include variable focus liquid lenses, liquid lens for focus and astigmatism control, auto focus lens modules, microscope auto focus modules, liquid lens driver ICs, and liquid lens development kits. The company’s products are used in industrial, biometrics, medical, and consumer applications. It sells its products through distributors. The company was founded in 2002 and is based in Lyon, France. As of December 29, 2016, Varioptic SA operates as a subsidiary of Invenios France SAS.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.
Innate Pharma S.A. is a clinical-stage biotechnology company based in Marseille, France, focused on developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in immunotherapies that leverage the innate immune system, particularly through its proprietary ANKET platform, which facilitates the creation of novel monoclonal antibodies. Innate Pharma's product pipeline includes several candidates in various stages of clinical development, such as Monalizumab, an immune checkpoint inhibitor for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody for cutaneous T-cell lymphoma. Other notable candidates include Avdoralimab, a therapeutic antibody targeting C5a receptors, and IPH5201, which aims to block the CD39 immunosuppressive pathway. Additionally, the company has formed strategic collaborations and licensing agreements with major pharmaceutical firms, enhancing its research capabilities and market reach. Founded in 1999, Innate Pharma continues to advance its innovative approaches to cancer treatment.
Innate Pharma S.A. is a clinical-stage biotechnology company based in Marseille, France, focused on developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in immunotherapies that leverage the innate immune system, particularly through its proprietary ANKET platform, which facilitates the creation of novel monoclonal antibodies. Innate Pharma's product pipeline includes several candidates in various stages of clinical development, such as Monalizumab, an immune checkpoint inhibitor for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody for cutaneous T-cell lymphoma. Other notable candidates include Avdoralimab, a therapeutic antibody targeting C5a receptors, and IPH5201, which aims to block the CD39 immunosuppressive pathway. Additionally, the company has formed strategic collaborations and licensing agreements with major pharmaceutical firms, enhancing its research capabilities and market reach. Founded in 1999, Innate Pharma continues to advance its innovative approaches to cancer treatment.